Integrative Genome-wide Analysis of the Determinants of RNA Splicing in Kidney Renal Clear Cell Carcinoma

We present a genome-wide analysis of splicing patterns of 282 kidney renal clear cell carcinoma patients in which we integrate data from whole-exome sequencing of tumor and normal samples, RNA-seq and copy number variation. We proposed a scoring mechanism to compare splicing patterns in tumor samples to normal samples in order to rank and detect tumor-specific isoforms that have a potential for new biomarkers. We identified a subset of genes that show introns only observable in tumor but not in normal samples, ENCODE and GEUVADIS samples. In order to improve our understanding of the underlying genetic mechanisms of splicing variation we performed a large-scale association analysis to find links between somatic or germline variants with alternative splicing events. We identified 915 cis- and trans-splicing quantitative trait loci (sQTL) associated with changes in splicing patterns. Some of these sQTL have previously been associated with being susceptibility loci for cancer and other diseases. Our analysis also allowed us to identify the function of several COSMIC variants showing significant association with changes in alternative splicing. This demonstrates the potential significance of variants affecting alternative splicing events and yields insights into the mechanisms related to an array of disease phenotypes.

[1]  A. Johnsen,et al.  Human red cell acid phosphatase (ACP1): the primary structure of the two pairs of isozymes encoded by the ACP1*A and ACP1*C alleles. , 1992, Biochimica et biophysica acta.

[2]  Brooke L. Fridley,et al.  GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer , 2013, Nature Genetics.

[3]  C Polychronakos,et al.  Type 1 diabetes and the OAS gene cluster: association with splicing polymorphism or haplotype? , 2005, Journal of Medical Genetics.

[4]  Adrian R Krainer,et al.  Splicing therapeutics in SMN2 and APOB. , 2009, Current opinion in molecular therapeutics.

[5]  M. A. Sanchez,et al.  Suppression of Glioma Progression by Egln3 , 2012, PloS one.

[6]  Vipin T. Sreedharan,et al.  Multiple reference genomes and transcriptomes for Arabidopsis thaliana , 2011, Nature.

[7]  Ding Ma,et al.  Selective Inhibitors of CYP2J2 Related to Terfenadine Exhibit Strong Activity against Human Cancers in Vitro and in Vivo , 2009, Journal of Pharmacology and Experimental Therapeutics.

[8]  HighWire Press,et al.  The journal of pharmacology and experimental therapeutics , 1909 .

[9]  HighWire Press,et al.  Cancer epidemiology biomarkers & prevention , 1991 .

[10]  E. Kandel,et al.  Proceedings of the National Academy of Sciences of the United States of America. Annual subject and author indexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[11]  B. Garcia,et al.  Proteomics , 2011, Journal of biomedicine & biotechnology.

[12]  W. Chung,et al.  Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk , 2013, PLoS genetics.

[13]  D. Smithers,et al.  Cancer Research , 1972, Nature.

[14]  BMC Bioinformatics , 2005 .

[15]  R. Sandberg,et al.  Full-Length mRNA-Seq from single cell levels of RNA and individual circulating tumor cells , 2012, Nature Biotechnology.

[16]  F. Collins,et al.  Potential etiologic and functional implications of genome-wide association loci for human diseases and traits , 2009, Proceedings of the National Academy of Sciences.

[17]  M. Green.  Pre-mRNA splicing. , 1986, Annual review of genetics.

[18]  Nazneen Rahman,et al.  Identification of nine new susceptibility loci for testicular cancer, including variants near DAZL and PRDM14 , 2013, Nature Genetics.

[19]  Nature Genetics , 1991, Nature.

[20]  K. Gichner,et al.  Annual review of genetics , 1987, Biologia Plantarum.

[21]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[22]  Watt,et al.  Journal of Cell Science , 1996, Nature.

[23]  Chris Sander,et al.  Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.

[24]  Chandra Sekhar Pedamallu,et al.  A Pan-Cancer Analysis of Transcriptome Changes Associated with Somatic Mutations in U2AF1 Reveals Commonly Altered Splicing Events , 2014, PloS one.

[25]  G. Holmgren,et al.  Journal of Medical Genetics. , 1963, British medical journal.

[26]  Christiana Kartsonaki,et al.  A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population , 2010, Nature Genetics.

[27]  S. Stamm,et al.  Alternative splicing and disease. , 2009, Biochimica et biophysica acta.

[28]  D. Koller,et al.  Characterizing the genetic basis of transcriptome diversity through RNA-sequencing of 922 individuals , 2013, Genome research.

[29]  A. Kornblihtt,et al.  The connection between splicing and cancer , 2006, Journal of Cell Science.

[30]  A. Whittemore,et al.  Common variants at 19p13 are associated with susceptibility to ovarian cancer , 2010, Nature Genetics.

[31]  J. Valcárcel,et al.  The spliceosome as a target of novel antitumour drugs , 2012, Nature Reviews Drug Discovery.

[32]  J. Mattick,et al.  Genome research , 1990, Nature.

[33]  Y. Bhutia,et al.  CNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cells. , 2011, Cancer research.

[34]  Pedro G. Ferreira,et al.  Transcriptome and genome sequencing uncovers functional variation in humans , 2013, Nature.

[35]  Ignacio I. Wistuba,et al.  Collagen XXIII: A Potential Biomarker for the Detection of Primary and Recurrent Non–Small Cell Lung Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[36]  A. J. Clifford,et al.  BIOCHIMICA ET BIOPHYSICA ACTA , 2022 .

[37]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[38]  Patrick Neven,et al.  Genome-wide association studies identify four ER negative–specific breast cancer risk loci , 2013, Nature Genetics.

[39]  Carolyn Gramling,et al.  How Fast Does Your Dinosaur Grow? , 2005, Science.

[40]  D. Sanghera,et al.  DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. , 1998, American journal of human genetics.

[41]  Quang Bui,et al.  Abnormal accumulation of human transmembrane (TMEM)-176A and 176B proteins is associated with cancer pathology. , 2012, Acta histochemica.

[42]  Israel Steinfeld,et al.  BMC Bioinformatics BioMed Central , 2008 .

[43]  Maode Lai,et al.  Identification of differentially expressed proteins in colorectal cancer by proteomics: Down‐regulation of secretagogin , 2006, Proteomics.

[44]  M. Alló,et al.  Alternative splicing: a pivotal step between eukaryotic transcription and translation , 2013, Nature Reviews Molecular Cell Biology.